ADC Therapeutics SA
ADCTADC Therapeutics SA in brief
ADC Therapeutics SA is a listed company in the Biotechnology industry, based in Switzerland. Its market value was $181 M on 8 October 2026, which makes it the 16,612th largest listed company in the world and the 165th largest in Switzerland on this site. In the year to December 2025 it had sales of $81 M and a net loss of $143 M. It employs about 116 people and Ameet Mallik is its chief executive. Its largest product and service lines by sales in 2025 were License revenues and royalties (10%), License revenues (6%) and Royalties (3%). By market, the largest shares of its 2025 sales came from USA (90%) and EMEA (10%). Its shares trade under the symbol ADCT (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About ADC Therapeutics SA
ADC Therapeutics is a Clinical Stage Oncology Biotechnology company, development and commercialization of next generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. The headquarters is in Switzerland.
ADC Therapeutics company annual revenue was 209 million USD and annual net loss was -155 million USD as on Dec-2022.
ADC Therapeutics SA timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 🔔Initial public offering on NYSEFinal prospectus filed with the SEC on 18 May 2020; shares registered for exchange trading on 11 May 2020.
Events of ADC Therapeutics SA from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Switzerland: #83 (Jan 2021) · #120 (Jan 2022) · #177 (Dec 2022) · #207 (Jul 2023) · #198 (Jan 2024) · #5 (Mar 2026) · #169 (Aug 2026) · #165 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.1×
- Price / book
- —
- Free cash flow yield
- -78.0%
- Net margin (TTM)
- -95.7%
- Operating margin
- -149.3%
- Return on equity
- —
- Liabilities / assets
- 157.5%
- Net debt
- $-404M
- Revenue growth
- +14.9%
- R&D / revenue
- 127.8%
- Revenue per employee
- $701 K
- Profit per employee
- $-1.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $81M | +14.9% | $-122M | $-143M | -175.3% |
| Dec 2024 | $71M | +1.8% | $-131M | $-158M | -222.8% |
| Dec 2023 | $70M | -66.9% | $-166M | $-240M | -345.1% |
| Dec 2022 | $210M | — | $-123M | $-157M | -74.9% |
| Dec 2020 | — | — | $-219M | $-246M | — |
| Dec 2019 | $2M | +105.3% | $-119M | $-116M | -4977.8% |
| Dec 2018 | $1M | — | $-126M | $-123M | -10798.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-141M | $0M | $-141M | $-1.12 | — |
| Dec 2024 | $-124M | $1M | $-125M | $-1.62 | — |
| Dec 2023 | $-119M | $3M | $-122M | $-2.94 | — |
| Dec 2022 | $-138M | $1M | $-139M | $-2.01 | — |
| Dec 2020 | $-169M | $1M | $-170M | — | — |
| Dec 2019 | $-122M | $0M | $-122M | — | — |
| Dec 2018 | $-121M | $1M | $-122M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $22M (+32.2% on a year earlier), net income $-25M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Nov 4, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- Oct 13, 20268-KCurrent reportMaterial agreement · Results of operations · Unregistered share sale
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 2, 20268-KCurrent reportDirectors or officers changed
- Jun 24, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 3, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 2, 20268-KCurrent reportShareholder vote
- May 4, 202610-QQuarterly report · period to Mar 2026
- May 4, 20268-KCurrent reportResults of operations
Official filings of ADC Therapeutics SA with the US Securities and Exchange Commission.
Annual results
- Revenue
- $81 M
- Operating income
- $-122 M
- Net income
- $-143 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $323 M
- Total liabilities
- $509 M
- Total equity
- $-186 M
As of December-2025
Top 100 institutional investors in ADC Therapeutics SA#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 12,576,184 | -12,076,184 (-48.99%) | 9.85% | $15 M | Nov 13, 2026 |
| 2 | Redmile Group, LLC | 11,584,552 | +57,842 (+0.50%) | 9.07% | $14 M | Nov 16, 2026 |
| 3 | TCG Crossover Management, LLC | 11,390,175 | 0 (0.00%) | 8.92% | $14 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 7,179,305 | +159,212 (+2.27%) | 5.62% | $9 M | Nov 13, 2026 |
| 5 | AIGH Capital Management LLC | 4,324,327 | New | 3.39% | $5 M | Nov 2, 2026 |
| 6 | Opaleye Management Inc. | 4,070,819 | +3,370,819 (+481.55%) | 3.19% | $5 M | Nov 16, 2026 |
| 7 | Goldman Sachs Group Inc | 3,485,435 | +1,571,011 (+82.06%) | 2.73% | $4 M | Nov 16, 2026 |
| 8 | Morgan Stanley | 2,717,262 | -333,911 (-10.94%) | 2.13% | $3 M | Nov 13, 2026 |
| 9 | Citadel Advisors LLC | 2,446,868 | +393,552 (+19.17%) | 1.92% | $3 M | Nov 16, 2026 |
| 10 | AQR Capital Management LLC | 2,250,433 | +1,592,308 (+241.95%) | 1.76% | $3 M | Nov 16, 2026 |
| 11 | State Street Corp | 1,702,853 | +17,017 (+1.01%) | 1.33% | $2 M | Nov 12, 2026 |
| 12 | Two Sigma Investments, LP | 1,615,636 | +842,222 (+108.90%) | 1.27% | $2 M | Nov 16, 2026 |
| 13 | D. E. Shaw & Co., Inc. | 1,514,496 | +795,176 (+110.55%) | 1.19% | $2 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 1,513,878 | +68,332 (+4.73%) | 1.19% | $2 M | Nov 6, 2026 |
| 15 | Bank Of America Corp /de/ | 1,289,144 | +938 (+0.07%) | 1.01% | $2 M | Nov 16, 2026 |
| 16 | Vanguard Portfolio Management LLC | 1,082,160 | +185,068 (+20.63%) | 0.85% | $1 M | Nov 13, 2026 |
| 17 | Acadian Asset Management LLC | 1,006,527 | +646,276 (+179.40%) | 0.79% | $1 M | Nov 9, 2026 |
| 18 | UBS Group AG | 773,698 | +253,405 (+48.70%) | 0.61% | $1 M | Nov 10, 2026 |
| 19 | Blue Owl Capital Holdings LP | 733,568 | 0 (0.00%) | 0.57% | $1 M | Nov 13, 2026 |
| 20 | Panagora Asset Management Inc | 695,401 | +122,585 (+21.40%) | 0.54% | $1 M | Nov 12, 2026 |
| 21 | Jane Street Group, LLC | 641,221 | +579,954 (+946.60%) | 0.50% | $1 M | Nov 12, 2026 |
| 22 | BNP Paribas Financial Markets | 632,568 | -20,281 (-3.11%) | 0.50% | $1 M | Nov 12, 2026 |
| 23 | Northern Trust Corp | 593,895 | -130 (-0.02%) | 0.47% | $1 M | Nov 16, 2026 |
| 24 | Platinum Investment Management LTD | 581,609 | 0 (0.00%) | 0.46% | $1 M | Nov 16, 2026 |
| 25 | Point72 Asset Management, L.P. | 447,786 | -3,201,358 (-87.73%) | 0.35% | $1 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Florida Trust Wealth Management Co | 400,000 | +169,565 (+73.58%) | 0.31% | $0 M | Nov 5, 2026 |
| 27 | Prosight Management, LP | 399,900 | -7,424,849 (-94.89%) | 0.31% | $0 M | Nov 13, 2026 |
| 28 | Renaissance Technologies LLC | 384,778 | New | 0.30% | $0 M | Nov 12, 2026 |
| 29 | Jacobs Levy Equity Management, Inc | 263,997 | +122,653 (+86.78%) | 0.21% | $0 M | Nov 16, 2026 |
| 30 | Charles Schwab Investment Management Inc | 258,687 | +34,629 (+15.46%) | 0.20% | $0 M | Nov 16, 2026 |
| 31 | Bank of New York Mellon Corp | 252,005 | +360 (+0.14%) | 0.20% | $0 M | Nov 5, 2026 |
| 32 | Commerce Bank | 235,849 | New | 0.18% | $0 M | Nov 12, 2026 |
| 33 | XTX Topco Ltd | 226,937 | +86,596 (+61.70%) | 0.18% | $0 M | Nov 16, 2026 |
| 34 | Russell Investments Group, Ltd. | 213,542 | -73,062 (-25.49%) | 0.17% | $0 M | Nov 6, 2026 |
| 35 | Nuveen, LLC | 181,527 | +4,834 (+2.74%) | 0.14% | $0 M | Nov 10, 2026 |
| 36 | FMR LLC | 179,171 | +46,396 (+34.94%) | 0.14% | $0 M | Nov 10, 2026 |
| 37 | Barclays PLC | 162,765 | +68,501 (+72.67%) | 0.13% | $0 M | Nov 6, 2026 |
| 38 | Shelton Capital Management | 130,724 | New | 0.10% | $0 M | Nov 16, 2026 |
| 39 | Rhumbline Advisers | 120,941 | +3,577 (+3.05%) | 0.09% | $0 M | Nov 10, 2026 |
| 40 | Alliancebernstein L.P. | 108,470 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 41 | Price T Rowe Associates Inc /MD/ | 103,721 | +28,861 (+38.55%) | 0.08% | $0 M | Nov 16, 2026 |
| 42 | Wilmington Savings Fund Society, FSB | 100,000 | 0 (0.00%) | 0.08% | $0 M | Oct 23, 2026 |
| 43 | Revolve Wealth Partners, LLC | 100,000 | 0 (0.00%) | 0.08% | $0 M | Oct 23, 2026 |
| 44 | Gsa Capital Partners LLP | 98,413 | +43,718 (+79.93%) | 0.08% | $0 M | Nov 16, 2026 |
| 45 | Cantor Fitzgerald, L. P. | 95,648 | New | 0.07% | $0 M | Nov 16, 2026 |
| 46 | Deutsche Bank AG\ | 70,970 | -12,474 (-14.95%) | 0.06% | $0 M | Nov 6, 2026 |
| 47 | Envestnet Asset Management Inc | 58,258 | New | 0.05% | $0 M | Nov 16, 2026 |
| 48 | Jpmorgan Chase & Co | 57,659 | -94,881 (-62.20%) | 0.05% | $0 M | Nov 12, 2026 |
| 49 | DAFNA Capital Management LLC | 57,081 | -20,000 (-25.95%) | 0.04% | $0 M | Nov 16, 2026 |
| 50 | Invesco Ltd. | 56,352 | +590 (+1.06%) | 0.04% | $0 M | Nov 12, 2026 |
| 51 | Vanguard Fiduciary Trust Co | 55,210 | -1,293 (-2.29%) | 0.04% | $0 M | Nov 13, 2026 |
| 52 | HRT Financial LP | 53,037 | New | 0.04% | $0 M | Nov 13, 2026 |
| 53 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 51,900 | +2,630 (+5.34%) | 0.04% | $0 M | Nov 16, 2026 |
| 54 | Magnetar Financial LLC | 39,092 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 55 | Wells Fargo & Company/mn | 38,922 | -268,222 (-87.33%) | 0.03% | $0 M | Nov 16, 2026 |
| 56 | Police & Firemen's Retirement System of New Jersey | 32,544 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 57 | DLK Investment Management, LLC | 30,467 | -2,688 (-8.11%) | 0.02% | $0 M | Oct 9, 2026 |
| 58 | State of Alaska, Department of Revenue | 30,000 | 0 (0.00%) | 0.02% | $0 M | Oct 15, 2026 |
| 59 | Susquehanna International Group, LLP | 29,390 | New | 0.02% | $0 M | Nov 16, 2026 |
| 60 | Vanguard Personalized Indexing Management, LLC | 26,948 | +9,941 (+58.45%) | 0.02% | $0 M | Nov 16, 2026 |
| 61 | Cetera Investment Advisers | 26,623 | New | 0.02% | $0 M | Nov 13, 2026 |
| 62 | Simplex Trading, LLC | 26,557 | +18,360 (+223.98%) | 0.02% | $0 M | Nov 4, 2026 |
| 63 | R Squared Ltd | 24,402 | +10,476 (+75.23%) | 0.02% | $0 M | Nov 6, 2026 |
| 64 | Saxony Capital Management, LLC | 23,768 | 0 (0.00%) | 0.02% | $0 M | Oct 15, 2026 |
| 65 | SEI Investments Co | 22,989 | -10,472 (-31.30%) | 0.02% | $0 M | Nov 10, 2026 |
| 66 | Cerity Partners LLC | 20,441 | -6,703 (-24.69%) | 0.02% | $0 M | Nov 13, 2026 |
| 67 | Lynx Capital Group LTD /adv | 20,000 | New | 0.02% | $0 M | Nov 4, 2026 |
| 68 | Graham Capital Management, L.P. | 17,235 | New | 0.01% | $0 M | Nov 16, 2026 |
| 69 | HSBC Holdings PLC | 16,660 | New | 0.01% | $0 M | Nov 16, 2026 |
| 70 | Wealth Enhancement Advisory Services, LLC | 16,439 | -2,904 (-15.01%) | 0.01% | $0 M | Oct 13, 2026 |
| 71 | Royal Bank Of Canada | 16,238 | +10,347 (+175.64%) | 0.01% | $0 M | Nov 16, 2026 |
| 72 | Prudential Financial Inc | 14,295 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 73 | Two Sigma Securities, LLC | 13,578 | New | 0.01% | $0 M | Nov 16, 2026 |
| 74 | ProShare Advisors LLC | 13,470 | -574 (-4.09%) | 0.01% | $0 M | Oct 29, 2026 |
| 75 | Pallas Capital Advisors LLC | 12,412 | -189 (-1.50%) | 0.01% | $0 M | Nov 12, 2026 |
| 76 | Simplicity Wealth,LLC | 11,391 | New | 0.01% | $0 M | Oct 23, 2026 |
| 77 | Commonwealth Equity Services, LLC | 11,110 | -4,409 (-28.41%) | 0.01% | $0 M | Nov 2, 2026 |
| 78 | CIBC Bancorp USA Inc. | 10,604 | New | 0.01% | $0 M | Nov 13, 2026 |
| 79 | LPL Financial LLC | 10,565 | +400 (+3.94%) | 0.01% | $0 M | Nov 6, 2026 |
| 80 | Perigon Wealth Management, LLC | 10,387 | -269 (-2.52%) | 0.01% | $0 M | Oct 22, 2026 |
| 81 | Tower Research Capital LLC (TRC) | 10,368 | -7,993 (-43.53%) | 0.01% | $0 M | Nov 16, 2026 |
| 82 | Aviso Wealth Management | 10,343 | 0 (0.00%) | 0.01% | $0 M | Nov 4, 2026 |
| 83 | Xponance LLC | 10,047 | New | 0.01% | $0 M | Nov 3, 2026 |
| 84 | New York State Common Retirement Fund | 9,100 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 85 | Legal & General Group Plc | 9,012 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 86 | Ameritas Investment Partners, Inc. | 6,859 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 87 | Citigroup Inc | 6,825 | -42,847 (-86.26%) | 0.01% | $0 M | Nov 4, 2026 |
| 88 | Optiver Holding B.V. | 3,977 | +1,271 (+46.97%) | 0.00% | $0 M | Nov 16, 2026 |
| 89 | Jones Financial Companies Lllp | 3,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 90 | Sterling Capital Management LLC | 2,392 | +590 (+32.74%) | 0.00% | $0 M | Oct 22, 2026 |
| 91 | GAMMA Investing LLC | 2,348 | +2,299 (+4691.84%) | 0.00% | $0 M | Oct 8, 2026 |
| 92 | Nisa Investment Advisors, LLC | 2,020 | +1,650 (+445.95%) | 0.00% | $0 M | Oct 20, 2026 |
| 93 | Caitong International Asset Management Co., Ltd | 1,912 | -5,136 (-72.87%) | 0.00% | $0 M | Oct 29, 2026 |
| 94 | California State Teachers Retirement System | 1,431 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 95 | SJS Investment Consulting Inc. | 877 | +845 (+2640.62%) | 0.00% | $0 M | Oct 26, 2026 |
| 96 | Arax Advisory Partners | 855 | -249 (-22.55%) | 0.00% | $0 M | Nov 12, 2026 |
| 97 | Vanguard Global Advisers, LLC | 635 | New | 0.00% | $0 M | Nov 13, 2026 |
| 98 | Osaic Holdings, Inc. | 509 | -3,500 (-87.30%) | 0.00% | $0 M | Nov 12, 2026 |
| 99 | Rockefeller Capital Management L.P. | 431 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 100 | Allworth Financial LP | 391 | +287 (+275.96%) | 0.00% | $0 M | Nov 17, 2026 |
Mutual funds holding ADC Therapeutics SA#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.74 M | $3 M | 2.1% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 523,857 | $2 M | 0.41% | 0.01% | +23% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.15 M | $1 M | 0.90% | <0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 316,782 | $1 M | 0.25% | 0.06% | +0.1% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 742,327 | $1 M | 0.58% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 668,942 | $1 M | 0.52% | <0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 360,391 | $0 M | 0.28% | 0.03% | +40% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 95,226 | $0 M | 0.07% | 0.02% | +21% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 258,687 | $0 M | 0.20% | <0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 202,930 | $0 M | 0.16% | <0.01% | −76% | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 177,078 | $0 M | 0.14% | 0.01% | +58% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 173,365 | $0 M | 0.14% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 152,716 | $0 M | 0.12% | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 42,246 | $0 M | 0.03% | 0.01% | +20% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 116,021 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 111,381 | $0 M | 0.09% | 0.02% | +59% | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 30,255 | $0 M | 0.02% | 0.07% | — | Mar 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 104,376 | $0 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 79,373 | $0 M | 0.06% | 0.02% | +389% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 78,102 | $0 M | 0.06% | <0.01% | +1.0% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 53,800 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 51,103 | $0 M | 0.04% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 49,840 | $0 M | 0.04% | <0.01% | +202% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 49,840 | $0 M | 0.04% | <0.01% | +202% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 47,041 | $0 M | 0.04% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 43,766 | $0 M | 0.03% | <0.01% | −9.2% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 34,700 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 29,928 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 9,269 | $0 M | <0.01% | <0.01% | +51% | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 26,855 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 8,000 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 24,276 | $0 M | 0.02% | 0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 23,314 | $0 M | 0.02% | <0.01% | +94% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 21,617 | $0 M | 0.02% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 20,505 | $0 M | 0.02% | <0.01% | −74% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 20,514 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 19,177 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 18,596 | $0 M | 0.01% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 16,432 | $0 M | 0.01% | <0.01% | +41% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 4,808 | $0 M | <0.01% | <0.01% | +29% | May 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 13,186 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 13,438 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 3,799 | $0 M | <0.01% | <0.01% | −28% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 3,759 | $0 M | <0.01% | <0.01% | −29% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 11,857 | $0 M | <0.01% | <0.01% | −84% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 11,430 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 3,124 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 10,003 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 2,526 | $0 M | <0.01% | <0.01% | −5.3% | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 8,122 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 7,557 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 6,859 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 6,990 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,000 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 5,372 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,524 | $0 M | <0.01% | <0.01% | −74% | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,966 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 2,876 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 2,691 | $0 M | <0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 2,357 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 1,756 | $0 M | <0.01% | <0.01% | −73% | Jul 31, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 988 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 642 | $0 M | <0.01% | <0.01% | +7.5% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 576 | $0 M | <0.01% | <0.01% | +37% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 64 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at ADC Therapeutics SA#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ameet MallikChief Executive Officer, Director | Grant or award | +675,000 | — | — | 2.12 M | Form 4 |
| filed | Peter J. GrahamChief Legal Officer | Grant or award | +221,100 | — | — | 841,640 | Form 4 |
| filed | Mohamed ZakiChief Medical Officer | Grant or award | +213,900 | — | — | 896,317 | Form 4 |
| filed | Jose CarmonaChief Financial Officer | Grant or award | +203,700 | — | — | 938,076 | Form 4 |
| filed | Viviane MongesDirector | Shares withheld for tax | -2,596 | $3.080 | $8 K | 186,447 | Form 4 |
| filed | Peter HugDirector | Shares withheld for tax | -2,156 | $3.080 | $7 K | 263,344 | Form 4 |
| filed | Ron SquarerDirector | Shares withheld for tax | -15,196 | $3.080 | $47 K | 123,431 | Form 4 |
| filed | Timothy CoughlinDirector | Shares withheld for tax | -12,600 | $3.080 | $39 K | 72,400 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: ADC Therapeutics SA#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Index membership
- : removed from S&P 500 (replaced by DFS)Discover Financial Services was listed on New York Stock Exchange.
Fails to deliver
- : 524 shares at $1.42
- : 10,900 shares at $1.06
- : 7 shares at $1.11
- : 5,985 shares at $1.32
- : 27 shares at $1.24
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
ADC Therapeutics SA scorecard#
Passes 4 of the 18 checks that could be worked out: strongest in growth (2 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 8, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median2.1×Price to sales 2.1× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-78.0%Free cash flow is -78.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 5
- ✓Revenue grew in the newest year14.8%Revenue up 14.8% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-27.1%-27.1% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-27.1%-27.1% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.12 vs -1.62Diluted EPS -1.12 in fiscal 2025 against -1.62 the year before (report's currency).
- ✓Net income higher than five years earlier-$143 M-$143 M in fiscal 2025 against -$246 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$143 MNet income -$143 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-149.3%-149.3% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-149.3%-149.3% in fiscal 2025 against -58.8% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities4.4×Current ratio 4.37 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-7.5×Operating income -7.5 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.99Z-score -6.99 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year30.8%Diluted shares up 30.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from ADC Therapeutics SA's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -149.3% | -60.5% | |
| Net margin | -175.3% | -68.9% | |
| Revenue growth, 3 years a year | -27.1% | 12.9% | |
| Revenue growth | 14.9% | 15.8% | |
| Free cash flow margin | -173.8% | -61.5% |
5of 8on the Piotroski tests of financial strength
- Net loss of $143 million, the 4th loss-making year in a row.
- Free cash flow was negative: -$141 million.
- The share count rose 30.8% in the year.
- Shareholders' equity is negative: -$186 million.
ADC Therapeutics SA: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 81+14.9%100% | 71+1.8%100% | 70−66.9%100% | 210+519%100% | 34—100% | 0−100%— | 2.3+105%100% | 1.1—100% | |
| Cost of revenue | 5.8−2.5%7.1% | 5.9+135%8.4% | 2.5−23.4%3.6% | 3.3r4.6+137%1.6% | 1.4—4.1% | 0—— | 0—0.0% | — | |
| Research and development | 104−5.1%128% | 110−13.8%155% | 127−31.8%183% | 186r188+18.0%88.8% | 158+11.2%466% | 142+32.1%— | 108−9.1%4596% | 118—10378% | |
| Selling and marketing | 43−1.5%53.3% | 44−23.4%62.1% | 57−16.8%82.6% | 69+6.6%32.9% | 65+193%191% | 22—— | 0—0.0% | 0—0.0% | |
| General and administrative | 37−12.7%44.9% | 42−13.5%59.1% | 48−35.0%69.6% | 74—35.5% | — | — | — | — | |
| Total costs and expenses | 203+0.7%249% | 201−14.5%284% | 236−29.3%339% | 333r334+12.7%159% | 296+34.8%872% | 219+80.1%— | 122−4.2%5203% | 127—11147% | |
| Operating income | −121—−149% | −131—−184% | −166—−239% | −123r−124—−58.8% | −262—−772% | −219—— | −119—−5103% | −126—−11047% | |
| Interest and finance income | 8.8−28.2%10.8% | 12+16.4%17.3% | 11+310%15.2% | 2.6r18+3791%1.2% | 0.1−92.1%0.2% | 0.8−63.1%— | 2.3−21.1%96.3% | 2.9—251% | |
| Interest expense and finance costs | 52+2.8%63.5% | 50+8.4%70.9% | 46+26.1%66.6% | 37r37+100%17.5% | 18+272%54.1% | 4.9+3058%— | 0.2—6.7% | 0—0.0% | |
| Share of profit of associates | 0—0.0% | −1.5—−2.2% | −5.5—−7.9% | −10—−4.8% | — | — | — | — | |
| Other non-operating income (expense) | −20—−24.7% | −25—−36.0% | −29—−42.3% | −23—−11.2% | — | — | — | — | |
| Income before tax | −142—−174% | −156—−220% | −195—−281% | −147r−155—−69.9% | −252—−742% | −246—— | −116—−4953% | −123—−10778% | |
| Income tax | 1.0+511%1.2% | 0.2−99.6%0.2% | 39+17127%56.2% | 0.2r1.1—0.1% | −21−6669%−63.3% | 0.3−43.8%— | 0.6+160%24.9% | 0.2—19.6% | |
| Net income including minority interests | — | — | — | −156—−74.2% | −230—−678% | −246—— | −116—−4978% | −123—−10798% | |
| Net income attributable to shareholders | −143—−175% | −158—−223% | −240—−345% | −157r−156—−74.9% | −230—−678% | −246—— | −116—−4978% | −123—−10798% | |
| Earnings per share, basic | -1.12—— | -1.62—— | -2.94—— | -2.01—— | — | — | — | — | |
| Earnings per share, diluted | -1.12—— | -1.62—— | -2.94—— | -2.01—— | — | — | — | — | |
| Shares, weighted average (basic) | 127+30.8%— | 97+18.9%— | 82+4.6%— | 78+1.8%— | 77+17.3%— | 65+32.7%— | 49+5.8%— | 47—— | |
| Shares, weighted average (diluted) | 127+30.8%— | 97+18.9%— | 82+4.6%— | 78—— | — | — | — | — | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 261+4.2%80.9% | 251−10.0%77.9% | 279−14.7%78.5% | 326−30.0%66.5% | 467+6.2%75.5% | 439+280%85.5% | 116−16.8%83.9% | 139—— | |
| Receivables | — | — | — | 73+141%14.9% | 30—4.9% | 0—0.0% | — | — | |
| Inventory | 4.2+85.9%1.3% | 2.3r18−86.1%0.7% | 16+34.0%4.6% | 12r19+8.6%2.5% | 11—1.8% | 0—0.0% | — | — | |
| Other current assets | 6.1−35.6%1.9% | 9.5+57.8%2.9% | 6.0r16−74.5%1.7% | 23r28+35.8%4.8% | 17+53.7%2.8% | 11+59.5%2.2% | 7.1—5.1% | — | |
| Current assets | 306+5.2%94.8% | 291r307−13.4%90.5% | 336−22.7%94.8% | 435r446−17.2%88.6% | 525+16.6%85.0% | 450+267%87.7% | 123—89.1% | — | |
| Property, plant and equipment | 0−100%0.0% | 5.1−9.7%1.6% | 5.6+67.6%1.6% | 3.4r3.3−17.5%0.7% | 4.1+150%0.7% | 1.6+18.4%0.3% | 1.4—1.0% | — | |
| Right-of-use (leased) assets | 1.3−84.5%0.4% | 8.4−20.5%2.6% | 11+52.2%3.0% | 6.9r6.7−3.6%1.4% | 7.2+129%1.2% | 3.1−36.1%0.6% | 4.9—3.6% | — | |
| Other intangible assets | — | — | — | 14+5.7%2.9% | 14+33.4%2.2% | 10+20.7%2.0% | 8.4—6.1% | — | |
| Investments in associates | — | 0−100%0.0% | 1.6−78.4%0.5% | 7.6—1.6% | — | — | — | — | |
| Non-current assets | — | — | — | 83−10.4%16.9% | 93+46.7%15.0% | 63+319%12.3% | 15—10.9% | — | |
| Total assets | 323+0.4%100% | 322−9.2%100% | 355−27.7%100% | 491r529−20.6%100% | 618+20.3%100% | 514+273%100% | 138—100% | — | |
| Accounts payable | 9.2−49.1%2.8% | 18+15.8%5.6% | 16+26.1%4.4% | 12+2.2%2.5% | 12+129%2.0% | 5.3+58.6%1.0% | 3.3—2.4% | — | |
| Debt due within a year | 3.0—0.9% | 0—0.0% | — | — | 6.6+81.1%1.1% | 3.6—0.7% | 0—0.0% | — | |
| Current liabilities | 70−12.8%21.7% | 80+18.9%25.0% | 68−17.4%19.1% | 82r99+10.8%16.7% | 74+82.8%12.0% | 40+103%7.9% | 20—14.5% | — | |
| Long-term debt | — | — | — | — | 87+151%14.1% | 35—6.8% | 0—0.0% | — | |
| Lease liabilities (non-current) | 1.0−87.1%0.3% | 8.0−21.5%2.5% | 10+55.1%2.9% | 6.6−6.1%1.3% | 7.0+184%1.1% | 2.5−45.2%0.5% | 4.5r3.9—3.3% | — | |
| Non-current liabilities | — | — | — | 341−9.6%69.6% | 378+174%61.2% | 138+1993%26.8% | 6.6—4.8% | — | |
| Total liabilities | 509−3.0%158% | 525+4.3%163% | 503+22.3%142% | 411r440−9.0%83.8% | 452+154%73.1% | 178+572%34.7% | 27—19.3% | — | |
| Retained earnings | −1,636—−506% | −1,493—−464% | −1,335—−376% | −1,095r−1,081—−223% | −925—−150% | −695—−135% | −449—−326% | — | |
| Shareholders' equity | −186—−57.5% | −203—−62.9% | −148−287%−41.8% | 79−48.4%16.2% | 154—24.9% | — | — | — | |
| Total equity | — | — | — | 89−46.6%18.1% | 166−50.5%26.9% | 336+202%65.3% | 111−12.0%80.7% | 126—— | |
| Total liabilities and equity | 323+0.4%100% | 322−9.2%100% | 355−27.7%100% | 491r529−20.6%100% | 618+20.3%100% | 514+273%100% | 138—100% | — | |
| Shares outstanding | 126+27.2%— | 99+20.1%— | 82+2.0%— | 81—— | — | 77+47.3%— | 52+8.9%— | 48—— | |
| Cash-flow statement | |||||||||
| Share-based compensation | 6.9+5.1%8.5% | 6.6−51.3%9.3% | 13−72.6%19.4% | 49−18.4%23.5% | 60+60.9%178% | 38+3265%— | 1.1+138%47.7% | 0.5—41.1% | |
| Cash from operating activities | −141—−174% | −124—−175% | −119—−171% | −138r−137—−65.9% | −233—−688% | −169—— | −122—−5196% | −121—−10646% | |
| Capital expenditure | −0.3—−0.3% | −0.9—−1.2% | −3.2—−4.6% | −0.7r−0.6—−0.3% | −3.4—−10.1% | −0.8—— | −0.4—−15.3% | −0.9—−82.8% | |
| Intangible assets bought | — | — | — | −1.7—−0.8% | −2.9—−8.7% | −2.0—— | −1.8—−76.5% | −1.5—−134% | |
| Cash from investing activities | 0.4—0.5% | −0.9—−1.2% | −3.2—−4.6% | −0.7r−2.5—−0.3% | −6.7—−19.7% | −2.8—— | −2.2—−96.1% | −2.5—−220% | |
| Debt issued | — | — | — | 0−100%0.0% | 50−21.2%146% | 63—— | 0—0.0% | 0—0.0% | |
| Shares issued | 86+42.6%106% | 61—85.4% | 0—0.0% | — | 0−100%0.0% | 433—— | 0—0.0% | 0—0.0% | |
| Shares bought back | — | — | — | — | 0—0.0% | 0—— | −0.1—−6.0% | 0—0.0% | |
| Cash from financing activities | 151+55.5%186% | 97+31.4%137% | 74—106% | −0.9r−0.6−100%−0.4% | 267−46.0%788% | 495+392%— | 101—4295% | −0.0—−2.1% | |
| Exchange-rate effect on cash | 0.3—0.4% | −0.1−145%−0.1% | 0.2—0.3% | −0.2−3567%−0.1% | 0.0−97.4%0.0% | 0.2+285%— | 0.1—2.6% | −0.1—−4.6% | |
| Report | 10-K | 10-K | 10-K | 10-K | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | 85+12.8%100% | 22+32.2%100% | 19+2.2%100% | 21−9.5%100% | 23*+36.4%100% | 16−11.0%100% | 19+8.2%100% | 23+27.6%100% | 17*—100% | 18—100% | 17—100% | 18—100% | |
| Research and development | 70−37.9%82.7% | 15−45.0%67.9% | 17−42.3%90.2% | 20−31.3%95.3% | 18*−32.9%78.9% | 27−17.5%163% | 30+23.9%160% | 29+12.4%126% | 27*—160% | 33—176% | 24—140% | 26—143% | |
| Selling and marketing | 46+7.7%54.1% | 8.7−18.8%39.9% | 13+23.9%65.3% | 13+20.4%60.9% | 12*+6.5%52.0% | 11+0.1%65.1% | 10−5.2%53.9% | 11−7.3%45.8% | 11*—66.5% | 11—57.8% | 11—61.5% | 11—63.1% | |
| General and administrative | 40+8.3%46.9% | 11+28.9%49.4% | 9.7+10.0%50.4% | 9.9−0.6%47.5% | 9.5*−1.7%41.0% | 8.3−16.8%50.7% | 8.8−13.8%46.8% | 10.0−17.3%43.2% | 9.6*—56.9% | 10—54.2% | 10—58.8% | 12—66.6% | |
| Total costs and expenses | 168−20.6%198% | 36−23.9%166% | 45−29.1%232% | 46−10.5%221% | 41*−17.0%178% | 47−12.3%289% | 63+35.6%334% | 51−0.3%224% | 49*—292% | 54—293% | 46—267% | 52—286% | |
| Operating income | −83—−97.7% | −14—−66.1% | −25—−132% | −25—−121% | −18*—−77.7% | −31—−189% | −44—−234% | −28—−124% | −32*—−192% | −36—−193% | −29—−167% | −34—−186% | |
| Interest and finance income | 7.8−14.4%9.2% | 1.6−34.5%7.5% | 1.8−5.9%9.5% | 2.0−2.9%9.6% | 2.4*−10.7%10.2% | 2.5−28.2%15.0% | 1.9−40.5%10.3% | 2.1−30.3%8.9% | 2.6*—15.6% | 3.4—18.6% | 3.3—18.7% | 2.9—16.3% | |
| Interest expense and finance costs | 53+4.1%62.0% | 14+2.5%63.2% | 14+3.9%70.2% | 12+1.0%59.2% | 13*+9.2%56.4% | 13+2.1%81.5% | 13+2.5%69.0% | 12−2.1%53.1% | 12*—70.5% | 13—71.0% | 13—72.8% | 12—69.2% | |
| Share of profit of associates | — | — | — | — | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | −0.3—−1.4% | −0.6—−3.4% | −0.7—−3.8% | |
| Other non-operating income (expense) | 1.3—1.5% | −11—−50.4% | 8.8—46.0% | −7.7—−37.0% | 11*+700%48.2% | −10.0—−60.9% | −11—−59.7% | −10.0—−43.3% | 1.4*—8.2% | −8.1—−43.6% | −6.7—−38.3% | −12—−67.3% | |
| Income before tax | −82—−96.2% | −25—−117% | −17—−86.1% | −33—−158% | −6.8*—−29.5% | −41—−249% | −55—−294% | −38—−167% | −31*—−184% | −44—−236% | −36—−205% | −46—−253% | |
| Income tax | −0.4−137%−0.5% | 0—0.0% | 0−100%0.0% | 0−100%0.0% | −0.4*—−1.8% | 0−100%0.0% | 1.3+436%6.7% | 0.2+1.2%0.7% | −0.3*—−1.9% | 0.1—0.5% | 0.2—1.3% | 0.2—0.9% | |
| Net income attributable to shareholders | −81—−95.7% | −25—−117% | −17—−86.1% | −33—−158% | −6.4*—−27.8% | −41—−249% | −57—−301% | −39—−168% | −31*—−182% | −44—−238% | −37—−210% | −47—−258% | |
| Earnings per share, basic | — | -0.16—— | -0.11—— | -0.21—— | — | -0.30—— | -0.50—— | -0.36—— | — | -0.42—— | -0.38—— | -0.56—— | |
| Earnings per share, diluted | — | -0.16—— | -0.11—— | -0.21—— | — | -0.30—— | -0.50—— | -0.36—— | — | -0.42—— | -0.38—— | -0.56—— | |
| Shares, weighted average (basic) | 155+13.9%— | 155+13.9%— | 155+36.3%— | 154+43.8%— | — | 136+30.2%— | 114+18.9%— | 107+29.9%— | — | 105—— | 96—— | 83—— | |
| Shares, weighted average (diluted) | 155+13.9%— | 155+13.9%— | 155+36.3%— | 154+43.8%— | — | 136+30.2%— | 114+18.9%— | 107+29.9%— | — | 105—— | 96—— | 83—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 189—73.9% | 189−19.4%73.9% | 219−17.2%78.4% | 231+18.6%79.2% | 261+4.2%80.9% | 235−14.4%81.0% | 265−11.8%82.3% | 195−16.9%71.4% | 251—77.9% | 274—78.6% | 300—80.7% | 234—76.1% | |
| Inventory | 5.6—2.2% | 5.6−68.8%2.2% | 4.9−72.2%1.8% | 4.8−72.6%1.6% | 4.2+85.9%1.3% | 18+12.3%6.2% | 18+16.9%5.5% | 17+9.1%6.4% | 2.3r18—0.7% | 16—4.6% | 15—4.1% | 16—5.2% | |
| Other current assets | 3.2—1.2% | 3.2−42.3%1.2% | 4.3−24.9%1.5% | 4.3−40.6%1.5% | 6.1−35.6%1.9% | 5.5−70.4%1.9% | 5.7−67.0%1.8% | 7.2−57.1%2.6% | 9.5—2.9% | 19—5.3% | 17—4.6% | 17—5.4% | |
| Current assets | 239—93.2% | 239−16.9%93.2% | 262−17.9%93.7% | 277+7.3%94.9% | 306+5.2%94.8% | 287−13.8%99.1% | 319−10.3%99.1% | 258−11.1%94.7% | 291r307—90.5% | 333—95.4% | 355—95.6% | 290—94.2% | |
| Property, plant and equipment | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0.0−100.0%0.0% | 5.2−10.9%1.9% | 5.1—1.6% | 5.7—1.6% | 5.5—1.5% | 5.8—1.9% | |
| Right-of-use (leased) assets | 1.0—0.4% | 1.0−28.0%0.4% | 1.1−26.0%0.4% | 1.2−85.4%0.4% | 1.3−84.5%0.4% | 1.4−84.8%0.5% | 1.5−84.6%0.5% | 8.2−18.2%3.0% | 8.4—2.6% | 9.2—2.6% | 9.7—2.6% | 10—3.3% | |
| Investments in associates | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0.3—0.1% | 0.9—0.3% | |
| Total assets | 256—100% | 256−11.7%100% | 279−13.1%100% | 291+7.0%100% | 323+0.4%100% | 290−17.0%100% | 322−13.5%100% | 273−11.5%100% | 322—100% | 349—100% | 372—100% | 308—100% | |
| Accounts payable | 5.6—2.2% | 5.6−31.2%2.2% | 13+32.7%4.6% | 5.3−66.0%1.8% | 9.2−49.1%2.8% | 8.1−43.5%2.8% | 9.6−10.2%3.0% | 16+8.9%5.7% | 18—5.6% | 14—4.1% | 11—2.9% | 14—4.6% | |
| Debt due within a year | 7.8—3.0% | 7.8—3.0% | 6.2—2.2% | 4.6—1.6% | 3.0—0.9% | — | — | — | 0—0.0% | — | — | — | |
| Current liabilities | 78—30.5% | 78+25.9%30.5% | 86+33.6%30.9% | 68+17.0%23.2% | 70−12.8%21.7% | 62−8.3%21.4% | 65+12.1%20.1% | 58−8.2%21.2% | 80—25.0% | 68—19.4% | 58—15.5% | 63—20.5% | |
| Lease liabilities (non-current) | — | — | 0.9−24.8%0.3% | 1.0−87.5%0.3% | 1.0−87.1%0.3% | 1.1−87.3%0.4% | 1.3−86.5%0.4% | 7.9−18.2%2.9% | 8.0—2.5% | 8.9—2.5% | 9.3—2.5% | 9.7—3.1% | |
| Total liabilities | 505—197% | 505−4.3%197% | 508−2.5%182% | 508−0.6%174% | 509−3.0%158% | 528+1.3%182% | 521+3.4%162% | 511+1.7%187% | 525—163% | 521—149% | 503—135% | 502—163% | |
| Retained earnings | −1,711—−669% | −1,711—−669% | −1,685—−603% | −1,669—−573% | −1,636—−506% | −1,630—−562% | −1,589—−494% | −1,532—−562% | −1,493—−464% | −1,463—−419% | −1,419—−382% | −1,382—−449% | |
| Shareholders' equity | −249—−97.4% | −249—−97.4% | −228—−81.7% | −216—−74.2% | −186—−57.5% | −238—−82.2% | −199—−61.9% | −238—−87.4% | −203—−62.9% | −172—−49.3% | −132—−35.4% | −194—−63.1% | |
| Total liabilities and equity | 256—100% | 256−11.7%100% | 279−13.1%100% | 291+7.0%100% | 323+0.4%100% | 290−17.0%100% | 322−13.5%100% | 273−11.5%100% | 322—100% | 349—100% | 372—100% | 308—100% | |
| Shares outstanding | 128—— | 128+13.4%— | 127+13.3%— | 127+28.2%— | 126+27.2%— | 113+16.5%— | 112+16.6%— | 99+19.8%— | 99—— | 97—— | 96—— | 83—— | |
| Cash-flow statement | |||||||||||||
| Share-based compensation | 12+49.8%13.9% | 4.1*+105%18.8% | 4.6*+151%23.6% | 2.4+0.9%11.7% | 0.7*−58.4%2.9% | 2.0*−28.7%12.2% | 1.8*−8.9%9.6% | 2.4+1432%10.5% | 1.6*—9.6% | 2.8*—15.2% | 2.0*—11.4% | 0.2—0.9% | |
| Cash from operating activities | −101—−118% | −28*—−128% | −12*—−61.3% | −30—−142% | −31*—−135% | −30*—−180% | −24*—−128% | −56—−245% | −22*—−129% | −25*—−136% | −33*—−189% | −44—−244% | |
| Capital expenditure | −0.0—−0.0% | 0*—0.0% | 0*—0.0% | −0.0—−0.2% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.3—−1.1% | −0.1*—−0.5% | −0.2*—−1.2% | −0.0*—−0.2% | −0.5—−2.9% | |
| Cash from investing activities | 0.6—0.7% | 0*—0.0% | 0*—0.0% | −0.0—−0.2% | 0.7*—2.9% | 0*—0.0% | 0*—0.0% | −0.3—−1.1% | −0.1*—−0.5% | −0.2*—−1.2% | −0.0*—−0.2% | −0.5—−2.9% | |
| Shares issued | 43−0.2%50.3% | −0.8*—−3.8% | 0*−100%0.0% | −0.0—−0.1% | 44*—189% | −0.5*—−2.9% | 43*—230% | 0—0.0% | 0*—0.0% | −1.2*—−6.6% | — | — | |
| Cash from financing activities | 54−41.4%64.0% | −2.1*—−9.7% | −0.1*−100%−0.5% | −0.6−315%−2.8% | 57*—248% | −0.2*—−1.2% | 94*−5.0%498% | 0.3−23.9%1.2% | −1.1*—−6.6% | −0.9*—−4.8% | 99*—567% | 0.4—2.0% | |
| Exchange-rate effect on cash | 0.1—0.1% | 0.1*+1233%0.4% | 0.0*−96.9%0.0% | −0.0−103%−0.0% | −0.0*—−0.1% | 0.0*−97.9%0.0% | 0.2*+1258%0.9% | 0.2—0.7% | −0.3*—−2.0% | 0.3*—1.6% | 0.0*—0.1% | −0.0—−0.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What ADC Therapeutics SA sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product revenues, net(total)$74 M90%+6.2%
- License revenues and royalties$8 M9.6%+401%
- License revenues$5 M6.2%—
- Royalties$3 M3.5%+80%
Business segments
- Reportable$81 M100%+15%
Countries and regions
- 🇺🇸 USA$74 M90%+6.2%
- EMEA$8 M9.6%+401%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where ADC Therapeutics SA operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇨🇭 Switzerland | Headquarters1 office | — |
| 🇬🇧 UK | 1 subsidiary | — |
| 🇺🇸 USA | 1 subsidiary | $74 M90% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at ADC Therapeutics SA#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Ameet Mallik | $2.5 M | $6.0 M | $1.4 M | $92 |
| 2024Ameet Mallik | $1.8 M | $4.1 M | $972 K | $52 |
| 2023Ameet Mallik | $3.8 M | $2.7 M | $2.8 M | $43 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at ADC Therapeutics SA#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 1 · Material agreement 4 · Unregistered share sale 4 · Shareholder vote 4 · Results announced 15
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Results announced | 8-K | |
| RestructuringMaterial agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How ADC Therapeutics SA compares in Biotechnology
- Market cap$181 M · higher than 43% of 726
- Revenue$81 M · higher than 67% of 647
- Net margin-95.7% · higher than 42% of 408
- Revenue growth14.8% · higher than 57% of 438
- Price / sales2.1× · lower than 84% of 339
- FCF yield-78.0% · higher than 14% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| ADC Therapeutics SA🇨🇭 | $181 M | — | -95.7% | +14.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 8, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at ADC Therapeutics SA? Verify and update this profile — free
Show ADC Therapeutics SA's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.